Skip to content
Prescott Bio Canada

MOTS-c: Research Summary

Published: 2026-08-03 · Last updated: 2026-08-03

Mechanism

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded in the 12S rRNA region of the mitochondrial genome. It was identified by the Cohen lab in 2015 and represents one of the first characterized peptides encoded within the mitochondrial genome itself rather than the nucleus. The peptide translocates to the nucleus under metabolic stress and modulates the expression of adaptive metabolic genes via the AMPK / folate cycle axis. Downstream effects reported in pre-clinical models include enhanced insulin sensitivity, increased glucose uptake, and adaptive resistance to metabolic stress. Circulating MOTS-c levels decline with age in humans.

Published trials

The primary literature is pre-clinical. Rodent models have reported improved insulin sensitivity, reduced diet-induced obesity, preserved lean mass and exercise capacity in aged mice, and metabolic protection in ischemia- reperfusion and heart-failure models. Cell-culture and tissue-level studies have characterized the AMPK-dependent signaling and the peptide's stress- induced nuclear translocation.

Human clinical trial data is very limited. Observational studies have reported associations between endogenous MOTS-c levels and glucose tolerance, physical activity, and age. Small early-phase interventional studies exist, but no large RCT has published pharmacokinetic, efficacy, or outcomes data for exogenous MOTS-c administration at the standard of a registration trial.

Safety profile

Rodent toxicology at typical research doses has not reported organ toxicity or acute adverse events. Published human safety data is thin — limited to small early-phase exposures — and no long-term controlled safety data exists. MOTS-c is not approved for human therapeutic use by any major regulator. Because it acts on AMPK and metabolic-stress adaptation pathways, theoretical interactions with metformin, GLP-1 receptor agonists, and other metabolic therapies are discussed in the literature but have not been characterized in human trials.

How it compares in its class

MOTS-c sits within the small class of mitochondrial-derived peptides (alongside humanin and the SHLP1–6 series). Within metabolic peptides more broadly, its mechanism is distinct: rather than acting on classical endocrine receptors (like the incretin agonists) it acts as a transcriptional regulator via AMPK. This positions it as an experimental tool compound in metabolic-aging research rather than a direct competitor to GLP-1-class weight-loss therapies.

References

  • PMID: 25738459 — Lee C et al., "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis." Cell Metab 2015.
  • PMID: 27817932 — Kim SJ et al., MOTS-c and exercise physiology. Front Physiol 2016.
  • PMID: 32041965 — Reynolds JC et al., MOTS-c and mitochondrial signaling. Nat Commun 2021.
  • DOI: 10.1016/j.cmet.2015.02.009 — Cell Metab 2015 MOTS-c identification (Lee et al.).

Buy MOTS-c in Canada: Prescott Bio Canada carries MOTS-c vials — HPLC + mass-spec tested, ships from Richmond BC in 2-4 business days.